Thomas D Bernier, Michael J Schontz, Saef Izzy, David Y Chung, Sarah E Nelson, Thabele M Leslie-Mazwi, Galen V Henderson, Hormuzdiyar Dasenbrock, Nirav Patel, Mohammad A Aziz-Sultan, Steven Feske, Rose Du, Yasser B Abulhasan, Mark R Angle
Delayed cerebral ischemia (DCI) following aneurysmal subarachnoid hemorrhage continues to be associated with high levels of morbidity and mortality. This complication had long been thought to occur secondary to severe cerebral vasospasm, but expert opinion now favors a multifactorial etiology, opening the possibility of new therapies. To date, no definitive treatment option for DCI has been recommended as standard of care, highlighting a need for further research into potential therapies. Milrinone has been identified as a promising therapeutic agent for DCI, possessing a mechanism of action for the reversal of cerebral vasospasm as well as potentially anti-inflammatory effects to treat the underlying etiology of DCI...
January 20, 2021: Journal of Neurosurgical Anesthesiology